ArticleCellular and molecular life sciences : CMLS2026
Exogenous lactate administration alleviates post-cardiac arrest brain injury by coordinating metabolic reprogramming and pathological mitophagy suppression.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe brain energy crisis following cardiac arrest and cardiopulmonary resuscitation (CA/CPR) is a major contributor to poor neurological outcomes. While lactate is traditionally viewed as a metabolic byproduct, its potential as an alternative metabolic substrate and as a signaling molecule remains controversial. This study investigates whether exogenous lactate administration (ELA) mitigates post-cardiac arrest brain injury (PCABI) and explores the underlying mechanisms.
methodsA rat model of CA/CPR and HT22 neurons subjected to oxygen-glucose deprivation/reoxygenation were employed. Multi-omics profiling, metabolic flux analysis, immunofluorescence, transmission electron microscopy, co-immunoprecipitation, and gene knockdown, were employed to dissect the underlying mechanisms.
resultsELA significantly improved 5-day survival, neurological function, and neuronal integrity in CA/CPR rats. Metabolomic and proteomic analyses revealed that ELA reprogrammed energy metabolism by alleviating the post-ischemic glycolytic surge, enhancing electron transport chain activity, and restoring the ATP/ADP ratio. In vitro, ELA’s neuroprotection was dependent on its cellular uptake and metabolic utilization, improving mitochondrial function, and reducing oxidative stress. Transcriptomic and ultrastructural analyses identified that ELA potently suppressed pathological mitophagy. Mechanistically, ELA promoted FOXO3A lactylation, thereby preventing its nuclear translocation and promoting its cytoplasmic retention and degradation. Consequently, the mitophagy receptor BNIP3 expression was downregulated, thereby inhibiting excessive mitophagy. The anti-mitophagic effect of ELA was abrogated following genetic ablation of Crebbp, an enzyme reported with lactyltransferase capability.
conclusionOur findings demonstrate that ELA alleviates PCABI by dually reprogramming energy metabolism and suppressing pathological mitophagy. These results position lactate not only as a metabolite intermediate but also as a potential therapeutic agent and signaling molecule in PCABI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.